Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2021-11-24 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
关于召开2021年第三次临时股东大会的通知
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed notice about convening the 2021 third extraordinary general meeting of shareholders for Tianjin Ruipu Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, registration methods, and proxy forms. There is no financial data or report content, but rather an announcement and instructions related to a shareholders' meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since the document is primarily a notice of the meeting and voting procedures rather than solicitation materials or proxy statements, it aligns best with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, but it is not merely announcing a report publication; it is a full notice of a shareholders meeting and voting details. Therefore, the best classification is DVA with high confidence.
2021-11-24 Chinese
关于使用募集资金置换预先投入募投项目的自有资金及已支付发行费用的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Tianjin Ruipu Biological Technology Co., Ltd. regarding the use of raised funds to replace self-owned funds previously invested in projects and paid issuance expenses. It includes details about the fundraising, approval by the board and supervisory committees, independent director opinions, and audit verification by an accounting firm. The document is a formal disclosure about the company's capital management and use of proceeds from a specific stock issuance. It does not contain comprehensive financial statements or quarterly/yearly financial results, nor is it a transcript, presentation, or legal proceeding. It is a specific update on capital usage related to fundraising activities, which fits the category of Capital/Financing Update (CAP). The document length is about 4876 characters, which is sufficient for a detailed announcement but not a full annual or interim report. Therefore, the best classification is CAP with high confidence.
2021-11-24 Chinese
以自有资金预先投入募投项目及支付发行费用情况鉴证报告
Regulatory Filings
2021-11-24 Chinese
第四届监事会第二十九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Tianjin Ruipu Biotechnology Co., Ltd. It discusses the approval of proposals related to the use of raised funds from a specific stock issuance, amendments to the company's articles of association, and revisions to management systems. It references the approval from the China Securities Regulatory Commission for a private placement of shares and confirms the receipt of funds. The document is a formal announcement of decisions made in a board meeting rather than a full financial report or detailed financial statements. It is also relatively short (1554 characters) and does not contain comprehensive financial data or analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-11-24 Chinese
银河证券关于天津瑞普生物技术股份有限公司使用募集资金置换预先投入募投项目的自有资金及已支付发行费用的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from China Galaxy Securities regarding the use of raised funds to replace self-owned funds previously invested in projects and paid issuance expenses by Tianjin Ruipu Biotechnology Co., Ltd. It includes specifics about the fundraising, board and supervisory approvals, independent director opinions, and an auditor's verification report. The document is not a full annual or interim financial report but rather a specialized audit/verification report related to the use of raised funds. It contains detailed financial figures and audit opinions but is not a general financial statement or earnings release. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report concerning the application of funds raised in a specific issuance. FY 2021
2021-11-24 Chinese
委托理财管理制度
Governance Information Classification · 95% confidence The document is titled '委托理财管理制度' which translates to 'Entrusted Wealth Management System' or 'Entrusted Financial Management System'. It is a detailed internal policy document outlining the principles, approval authorities, management, risk control, and operational procedures for the company's entrusted financial management activities. It references regulatory rules from the Shenzhen Stock Exchange and internal governance but does not contain financial statements, earnings data, or audit results. The document is a governance or internal control policy rather than a financial report or announcement. It is not a report publication announcement since it is substantive and not merely announcing a report. It is not a regulatory filing or certification letter. The content fits best under Governance Information (CGR) as it details internal rules and governance practices related to financial management.
2021-11-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.